Eric H. Bjerkholt
2019 - Aimmune Therapeutics
In 2019, Eric H. Bjerkholt earned a total compensation of $2M as Chief Financial Officer at Aimmune Therapeutics, a 3% decrease compared to previous year.
Compensation breakdown
| Bonus | $4,190 |
|---|---|
| Non-Equity Incentive Plan | $179,489 |
| Option Awards | $1,113,557 |
| Salary | $436,500 |
| Stock Awards | $311,325 |
| Other | $2,000 |
| Total | $2,047,061 |
Bjerkholt received $1.1M in option awards, accounting for 54% of the total pay in 2019.
Bjerkholt also received $4.2K in bonus, $179.5K in non-equity incentive plan, $436.5K in salary, $311.3K in stock awards and $2K in other compensation.
Rankings
In 2019, Eric H. Bjerkholt's compensation ranked 5,814th out of 13,971 executives tracked by ExecPay. In other words, Bjerkholt earned more than 58.4% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,814 out of 13,971 | 58th |
Division Manufacturing | 2,177 out of 5,701 | 62nd |
Major group Chemicals And Allied Products | 783 out of 2,200 | 64th |
Industry group Drugs | 659 out of 1,886 | 65th |
Industry Pharmaceutical Preparations | 485 out of 1,398 | 65th |
Source: SEC filing on April 9, 2020.
Bjerkholt's colleagues
We found four more compensation records of executives who worked with Eric H. Bjerkholt at Aimmune Therapeutics in 2019.